MORPHOSYS AG

ISIN: **DE0006632003** WKN: **663200** Asset Class: **Stock**

Company

morphosys

2024/07/31 17:40:37


Price 67.90EUR

Difference

0.00%(0.00)

Contact Details

MORPHOSYS AG Tel: +49-89-89927-0 -- Fax: +49-89-89927-2



Company Profile

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	202	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity_
Current assets	814,021,000		1,089,040,000		1,132,969,000	
Common stock capital		37,655,000		34,231,000		34,231,000
Fixed assets	1,212,289,000		1,307,891,000		1,423,284,000	
Equity capital of a company		49,049,000		157,409,000		244,875,000
Cash and cash equivalents	158,499,000		402,350,000		123,248,000	
Accrued liabilities		28,363,000		8,674,000		1,576,000
Other assets	-		-		-	
Current liabilities		264,309,000		278,346,000		284,538,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,712,952,000		1,961,176,000		2,026,839,000
Different income		-		-		-
Other liabilities		1,425,221,000		1,616,129,000		1,681,067,000
Total assets	2,026,311,000	2,026,311,000	2,396,932,000	2,396,932,000	2,556,254,000	2,556,254,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	564	647	732
Equity ratio	2.42%	6.57%	9.58%
Debt-equity ratio	4,031.18%	1,422.74%	943.90%

Others

	2023	2022	2021
Tax Expense Rate	0.65%	772.40%	12.96%

MORPHOSYS AG

ISIN: DE0006632003 WKN: 663200 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	238,278,000	278,267,000	179,611,000
Net income	-189,734,000	-151,058,000	-514,460,000
EBIT	-107,488,845	133,998,322	-525,707,538
Operating income before taxes	-182,748,000	21,825,000	-591,050,000
Cash Flow	-279,448,000	-366,845,000	-484,572,000
Net interest income	-75,259,000	-112,172,000	-65,343,000
Research and development expenses	266,646,000	284,543,000	219,072,000
Income taxes	-1,188,000	168,578,000	-76,590,000
Result from investments in subsidaries, associates and other	-8,174,000	-4,305,000	0
Revenues per employee	422,479	430,088	245,371

Board of Directors	
Heinrich Moisa	Member of Supervisory Board
Romain Lege	Member of Supervisory Board
Sharon Curran	Member of Supervisory Board
Silke Mainka	Member of Supervisory Board

Members of Management Board			
Arkadius Pichota	Chairman of Managing Board		
Barbara Krebs-Pohl	Member of Executive Committee		
Tim Demuth	Member of Executive Committee		
Charlotte Lohmann	Member of Executive Committee		
Lukas Gilgen	Member of Executive Committee		